UK-based CRO Cresset and Elixir aim to brew new drug discovery platform

18-Oct-2018 - Last updated on 08-Aug-2019 at 20:31 GMT

(Image: Getty/monsitj)

The CRO and software provider for small molecule discovery, Cresset, is collaborating with Elixir to create a new platform for efficient drug discovery.

The collaboration brings the two companies together to combine technologies, including Elixir’s chemTrax platform, which provides a visual workflow for hypothesis capture, compound design prioritization, and synthesis tracking.

CEO of Elixir Software, Paul Faulder said that the chemTrax platform will deliver increased efficiencies in new molecule discovery.

“The modern paradigm in drug discovery is highly collaborative, both internally and externally, with design partners and CRO’s for instance,” said Cresset CEO Robert Scoffin in a press release. “[The] Key to making this paradigm efficient is effective real-time communications and the ability to manage and track all aspects of the design, make, test, analyze (DMTA) process.”

The UK-based contract research organization (CRO), Cresset, brings its own software and discovery services to the partnership.

“By combining these technologies, it is our ultimate vision to create a platform that enables efficient, modern drug discovery on a global scale and focusing on interactive communication,” said Tim Cheeseright, director of products at Cresset.

The companies were unable to provide any further comment at this time.